In the case of a special meeting of shareholders (which is not also an annual meeting), notice to the company must be made not later than the close of business on the 10th day following the day on which the first public announcement of the date of the special meeting was made. About Cardiome Pharma Corp. Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients around the world. Cardiome has one marketed product, BRINAVESS™ (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM).